JW Pharmaceutical Corporation (001060.KS)
ValueMarkers Composite Index
42% below intrinsic value ($38)
JW Pharmaceutical Corporation (001060.KS) — VMCI valuation read
The headline on JW Pharmaceutical Corporation (001060.KS) is a 65/100 VMCI score, set against a Healthcare sector median of 50. That 15-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.
001060.KS insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.
**Investor frame.** 001060.KS trades at 17.0x earnings, 6% below the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -2.1x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on 001060.KS.
001060.KS rose 1.9% over the trailing 7 days, with a -23.4% read on a 30-day basis.
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.